Early tocilizumab treatment could improve survival among COVID-19 patients.Clin Exp Rheumatol. 2020 May-Jun; 38(3):578.CE
MeSH
Pub Type(s)
Letter
Language
eng
PubMed ID
32456769
Citation
Campins, Lluis, et al. "Early Tocilizumab Treatment Could Improve Survival Among COVID-19 Patients." Clinical and Experimental Rheumatology, vol. 38, no. 3, 2020, p. 578.
Campins L, Boixeda R, Perez-Cordon L, et al. Early tocilizumab treatment could improve survival among COVID-19 patients. Clin Exp Rheumatol. 2020;38(3):578.
Campins, L., Boixeda, R., Perez-Cordon, L., Aranega, R., Lopera, C., & Force, L. (2020). Early tocilizumab treatment could improve survival among COVID-19 patients. Clinical and Experimental Rheumatology, 38(3), 578.
Campins L, et al. Early Tocilizumab Treatment Could Improve Survival Among COVID-19 Patients. Clin Exp Rheumatol. 2020 May-Jun;38(3):578. PubMed PMID: 32456769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Early tocilizumab treatment could improve survival among COVID-19 patients.
AU - Campins,Lluis,
AU - Boixeda,Ramon,
AU - Perez-Cordon,Laia,
AU - Aranega,Raquel,
AU - Lopera,Carlos,
AU - Force,Lluis,
Y1 - 2020/05/27/
PY - 2020/05/17/received
PY - 2020/05/20/accepted
PY - 2020/5/28/entrez
PY - 2020/5/28/pubmed
PY - 2020/6/5/medline
SP - 578
EP - 578
JF - Clinical and experimental rheumatology
JO - Clin Exp Rheumatol
VL - 38
IS - 3
SN - 0392-856X
UR - https://www.unboundmedicine.com/medline/citation/32456769/Early_tocilizumab_treatment_could_improve_survival_among_COVID_19_patients_
DB - PRIME
DP - Unbound Medicine
ER -